Publications & Resources

Publications on vidutolimod (CMP-001)

1. Lemke-Miltner, Caitlin D., et al. “Antibody Opsonization of a TLR9 Agonist–Containing Virus-like Particle Enhances In Situ
   Immunization.” The Journal of Immunology 204.5 (2020): 1386-1394.
2. Cheng Y, Lemke-Miltner CD, Wongpattaraworakul W, Wang Z, Chan CHF, Salem AK, Weiner GJ, Simons AL. In situ immunization
   of a TLR9 agonist virus-like particle enhances anti-PD1 therapy. J Immunother Cancer. 2020 Oct;8(2):e000940. doi: 10.1136/
   jitc-2020-000940. PMID: 33060147; PMCID: PMC7566437.
3. Younes AI, Barsoumian HB, Sezen D, Verma V, Patel R, Wasley M, Hu Y, Dunn JD, He K, Chen D, Menon H, Masrorpour F, Gu M,
   Yang L, Puebla-Osorio N, Cortez MA, Welsh JW. Addition of TLR9 agonist immunotherapy to radiation improves systemic
   antitumor activity. Transl Oncol. 2021 Feb;14(2):100983. doi: 10.1016/j.tranon.2020.100983. Epub 2020 Dec 16. PMID:
   33340886; PMCID: PMC7750418.
4. Miller, Ann M., et al. “Intraperitoneal CMP-001: a novel immunotherapy for treating peritoneal carcinomatosis of gastrointestinal
   and pancreaticobiliary cancer.” Annals of surgical oncology 28 (2021): 1187-1197.
5. Sabree, Shakoora A., et al. “Direct and indirect immune effects of CMP-001, a virus-like particle containing a TLR9 agonist.” Journal
   for Immunotherapy of Cancer 9.6 (2021).

Review Articles – pDC

1. Lombardi, Vincent C., Svetlana F. Khaiboullina, and Albert A. Rizvanov. “Plasmacytoid dendritic cells, a role in neoplastic prevention
   and progression.” European journal of clinical investigation 45 (2015): 1-8.
2. Di Domizio, Jeremy, Olivier Demaria, and Michel Gilliet. “Plasmacytoid dendritic cells in melanoma: can we revert bad into good?.”
   Journal of Investigative Dermatology 134.7 (2014): 1797-1800.
3. Demoulin, Stéphanie, et al. “Tumor microenvironment converts plasmacytoid dendritic cells into immunosuppressive/tolerogenic
   cells: insight into the molecular mechanisms.” Journal of leukocyte biology 93.3 (2013): 343-352.

Patient Resources